Table 4 The treatment of psychiatric symptoms in patients with Parkinson’s disease by the composite neurologist population and psychiatrists
From: Managing non-motor symptoms of Parkinson disease in China: clinical perspectives
Items | Specialty | Specialty | ||||
|---|---|---|---|---|---|---|
Neurologist | Psychiatrists | p value | Movement disorder specialist | Psychiatrists | p value | |
(n = 854) | (n = 59) | (n = 259) | (n = 59) | |||
Depression/anxiety | ||||||
Dopamine agonists, n(%) | 283(33.1) | 4(6.8) | < 0.001 | 124(47.9) | 4(6.8) | < 0.001 |
SNRIs, n(%) | 123(14.4) | 9(15.3) | 0.094 | 38(14.7) | 9(15.3) | 0.909 |
SSRIs, n(%) | 326(38.2) | 34(57.6) | < 0.001 | 75(29.0) | 34(57.6) | < 0.001 |
NaSSAs, n(%) | 31(3.6) | 0(0) | 0.328 | 9(3.5) | 0 | 0.146 |
Benzodiazepines, n(%) | 13(1.5) | 2(3.4) | 0.397 | 0 | 2(3.4) | 0.003 |
Chinese patent medicine, n(%) | 14(1.6) | 2(3.4) | 0.286 | 6(2.3) | 2(3.4) | 0.635 |
rTMS, n(%) | 270(31.6) | 26(44.1) | 0.048 | 108(41.7) | 26(44.1) | 0.739 |
MECT, n(%) | 32(3.8) | 6(10.2) | 0.017 | 15(5.8) | 6(10.2) | 0.222 |
PD psychosis | ||||||
quetiapine, n(%) | 456(53.4) | 33(56.0) | 0.706 | 195(75.3) | 33(56.0) | 0.003 |
Olanzapine, n(%) | 407(47.7) | 31(52.6) | 0.468 | 102(39.4) | 31(52.5) | 0.064 |
Clozapine, n(%) | 295(34.5) | 15(25.4) | 0.153 | 145(56.0) | 15(25.4) | < 0.001 |
aripiprazole, n(%) | 49(5.7) | 18(30.5) | < 0.001 | 16(6.2) | 18(30.5) | < 0.001 |
Risperidone, n(%) | 172(20.1) | 13(22.0) | 0.726 | 54(20.9) | 13(22.0) | 0.84 |